Medigen, Inc. is doubling the amount of space leased at Riverside Technology Park in Frederick, MD to 12,000 square feet, to expand operations. The company intends to increase its manufacturing workforce, with the additional space expected to optimize the company’s proprietary vaccine pipeline development, as well as contract manufacturing services. 
 
The new lease represents a 100% increase in the aggregate office, research, manufacturing, and flexible space to be used by Medigen’s growing vaccine development and manufacturing operations. Medigen’s vaccines are intended primarily for high-impact pathogens capable of causing global epidemics and pandemics, and can be used by the first responders and emergency personnel, travelers and local populations in the affected areas.
 
Peter Pushko, Medigen’s President and Chief Scientific Officer, said, “In order for us to continue to support the growth of our vaccine development and contract development and manufacturing (CDMO) operations, we needed to expand our facility’s footprint as well as the employee count. Our newly leased space, which extends our main facility, should help us achieve our goals and further improve our operations. We are very excited about the future of Medigen Inc., with the product pipeline, a talented and growing team, current CDMO contracts, and potential partnerships.”